REGN 3470/3471/3479

Drug Profile

REGN 3470/3471/3479

Alternative Names: REGN3470-3471-3479

Latest Information Update: 02 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ebola virus infections
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Ebola virus infections

Most Recent Events

  • 01 Jun 2016 REGN 3470/3471/3479 receives Orphan Drug status for Ebola virus infections (Combination therapy) in USA
  • 01 May 2016 Phase-I clinical trials in Ebola virus infections (In volunteers) in USA (IV) (NCT02777151)
  • 30 Apr 2016 Regeneron plans a phase I trial in healty volunteers in USA (NCT02777151)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top